For EGFR WT patients, the relationship between MET amplification and PD-L1 expression may be critical for personalized cancer treatment that downregulates the RAS/MAPK pathway and where PD-L1 inhibitors are likely to be effective given the over-expression of PD-L1 seen in this patient population. Here, MET is linked to cancer.